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Available online xxxxBackground: Psychosis relapses are common, have profound adverse consequences for patients, and are costly to
health services. ‘Early signs’ have beenused to predict relapse, in the hope of prevention ormitigation,withmod-
erate sensitivity and speciﬁcity.We investigated the feasibility and validity of adding ‘basic symptoms’ to conven-
tional early signs and monitoring these using a smartphone app.
Methods: Individuals (n= 18) experiencing a relapse within the past year were asked to use a smartphone app
(‘ExPRESS’) weekly for six months to report early signs, basic symptoms and psychotic symptoms. Above-
threshold increases in app-reported psychotic symptoms prompted a telephone interview (PANSS positive
items) to assess relapse.
Results: Participants completed 65% app assessments and 58% telephone interviews. App items showed high con-
current validity with researcher-rated psychotic symptoms and basic symptoms over six months. There was ex-
cellent agreement between telephone call and face-to-face assessed psychotic symptoms. The primary relapse
deﬁnition, based on telephone assessment and casenotes, compared well with a casenote-only deﬁnition but
had better speciﬁcity.Mixed-effectsmodels provided preliminary evidence of concurrent and predictive validity:
early signs and basic symptomswere associated with most app-assessed psychotic symptom variables the same
week and with a number of psychotic symptoms variables three weeks later; adding basic symptoms to early
signs improved model ﬁt in most of these cases.
Conclusions: This is the ﬁrst study to test a smartphone app formonitoring early signs and basic symptoms as pu-
tative relapse predictors. It demonstrates thatweekly app-basedmonitoring is feasible, valid and acceptable over
six months.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Smartphone1. Introduction
Psychosis relapses are associated with worse outcomes by almost
every measure (Almond et al., 2004; Andrew et al., 2012; Appleby,
1992; Birchwood et al., 2000; Gumley and Schwannauer, 2006; Iqbal
et al., 2000; Maclean, 2008; Wiersma et al., 1998; Wu et al., 2005). Re-
lapse signatures, idiosyncratic combinations of warning signs, have, Brunswick Street, Manchester
isner),
anchester.ac.uk (N. Berry),
ugh@manchester.ac.uk
rake).
. This is an open access article under
, N. Berry, et al., Feasibility o
arch, https://doi.org/10.1016/been used to predict relapse in the hope of prevention or mitigation
but have only moderate sensitivity and speciﬁcity (Eisner et al., 2013).
To improve predictive power, we investigated adding basic symptoms
(Schultze-Lutter et al., 2007a) to pre-existing putative predictors (con-
ventional early signs) (Birchwood et al., 1989) and using a smartphone
application (‘app’) to facilitate prompt identiﬁcation of these.
Incorporating both basic symptoms and conventional early signs of
relapse into personalized relapse signatureswill likely achieve better re-
lapse prediction than has previously been demonstrated (Eisner et al.,
2013). Basic symptoms are subtle, subjective changes in individuals' ex-
periences of themselves (e.g. mild cognitive problems) and the world
around them (e.g.more vivid colors)whichpredictﬁrst episodes of psy-
chosis (Fusar-Poli et al., 2012; Schultze-Lutter et al., 2007b). There is
preliminary evidence that basic symptoms also predict relapses ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
f using a smartphone app to assess early signs, basic symptoms and
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2 E. Eisner et al. / Schizophrenia Research xxx (xxxx) xxxpsychosis (Bechdolf et al., 2002; Eisner et al., 2018; Gaebel and Riesbeck,
2014) but there are no comprehensive, prospective studies examining
this. A well-powered, methodologically sound, prospective study to es-
tablish whether basic symptoms predict relapses of psychosis is needed.
We tested the feasibility of carrying out such a study using a smartphone
app, ExPRESS (Experiences of Psychosis Relapse: Early Subjective Signs)
(Eisner et al., 2019), which collects weekly assessments of early signs,
basic symptoms and psychotic symptoms.
Existing early signs studies have typically used pen and paper ques-
tionnaires (Birchwood et al., 1989; Gaebel et al., 1993; Gaebel and
Riesbeck, 2007, 2014; Gleeson et al., 2005; Gumley et al., 2015; Hirsch
and Jolley, 1989; Jørgensen, 1998; Malla and Norman, 1994; Marder
et al., 1991; Marder et al., 1994; Subotnik and Neuchterlein, 1988; Tait
et al., 2002; Tarrier et al., 1991) or text message systems (Spaniel
et al., 2018; Spaniel et al., 2007; Spaniel et al., 2008) to examine the pre-
dictive value of conventional early signs of relapse. Compared to these
methods, smartphone apps have a number of advantages: apps can be
accessed at the individual's convenience (Ben-Zeev et al., 2013), de-
creasing participant burden and increasing ecological validity (Bucci
et al., 2018); apps can automatically supply surveys and securely upload
responses; ﬁnally, apps aremore acceptable to individuals with psycho-
sis than text message systems (Ainsworth et al., 2013).
A number of symptom monitoring apps prospectively assessing
symptom course have been tested (Ainsworth et al., 2013; Barnett
et al., 2018; Ben-Zeev et al., 2014; Ben-Zeev et al., 2017; Ben-Zeev
et al., 2018; Bucci et al., 2018; Kumar et al., 2018; Meyer et al., 2018;
Niendam et al., 2018; Palmier-Claus et al., 2012). Most monitor individ-
uals' currentmental state rather than aiming to elicit symptoms predic-
tive of relapse. Two assessed symptoms overlapping somewhat with
conventional early signs (e.g. anxiety, confusion), but did not measure
relapse (Kumar et al., 2018; Niendam et al., 2018). A small pilot study
(Barnett et al., 2018) collected both self-reported early signs via an
app and relapse as an outcome, but the focus of the published paper
wasmainly on the predictive value of passively collected data, with lim-
ited details of early signs data reported. Although a number of studies
have reported good correspondence between passively collected data
and outcomes (Barnett et al., 2018; Meyer et al., 2018; Wang et al.,
2016;Wang et al., 2017), this was not the focus of the current study. In-
stead, we aimed to further reﬁne the predictive value of app-based
monitoringby addingbasic symptoms to conventional early signs as pu-
tative relapse predictors.
The current study tested the methodology for a planned large-scale
study examining whether basic symptoms are valuable relapse predic-
tors. There were four speciﬁc aims:
i) to explore the feasibility of using a smartphone app (ExPRESS)
for weekly monitoring of early signs, basic symptoms, psychotic
symptoms and relapse over six months;
ii) to assess the concurrent and preliminary predictive validity of
using personalized relapse signatures integrating basic symp-
toms and conventional early signs;
iii) to examine the validity of an operational deﬁnition of relapse
using a combination of smartphone app assessment, verbal tele-
phone assessment and casenote examination;
iv) to examine the acceptability of the study procedures.
2. Materials and methods
2.1. Study design
This study consisted of three phases. First, cross-sectional assessments
characterized the sample and checked eligibility for the next phase. Sec-
ond, eligible participants used ExPRESS for six months and received tele-
phone calls from the researcher (prospective, longitudinal phase). Finally,
after six months the acceptability of the study procedures was exploredPlease cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
psychotic symptoms o..., Schizophrenia Research, https://doi.org/10.1016using qualitative interviews. The study was carried out in accordance
with the Declaration of Helsinki (World Medical Association, 2013), ethi-
cal approvalwas obtained fromGreaterManchesterWest Research Ethics
Committee (14/NW/1471) and the study was registered (ClinicalTrials.
gov: NCT03558529).2.2. Participants
Participants were recruited from three Mental Health Trusts in
North-West England between June 2015 and June 2016. Inclusion
criteria were: schizophrenia spectrum diagnosis (Diagnostic and Statis-
tical Manual of Mental Disorders, 4th Edition; DSM-IV) (Sheehan et al.,
1998); ≥1 acute psychotic episode in the past year (admission to crisis
team or hospital; or exacerbation of psychotic symptoms lasting
≥2 weeks and leading to a change in management), or ≥2 episodes in
the past 2 years, including index episode; currently prescribed antipsy-
choticmedication; age over 18 years;ﬁxed abode;ﬂuent in English; suf-
ﬁciently stable to take part (able to complete screening assessment); no
current alcohol or drug dependence (Structured Clinical Interview for
DSM-IV) (First et al., 1996); informed consent. To progress beyond
baseline assessment, individuals must have reported basic symptoms
which began or increased prior to a recent episode of psychosis.2.3. ExPRESS app
App design is detailed elsewhere (Eisner et al., 2019), with
screenshots provided in Supplementary Fig. 1. Brieﬂy, ExPRESS is an an-
droid smartphone app which prompts participants once a week to an-
swer a personalized set of questions regarding psychotic symptoms
(PANSS positive items) (Ainsworth et al., 2013; Kay et al., 1987;
Palmier-Claus et al., 2012), mood symptoms (Calgary Depression Scale)
(Addington et al., 1993), basic symptoms (Basic Symptoms Checklist,
BSC) (Eisner et al., 2019) and early signs of relapse (Early Signs Scale,
ESS) (Birchwood et al., 1989) within the past week. Participants have a
24-h window each week to respond to the question set. Responses are
uploaded automatically to a secure server, accessible to the research
team via a password protected web interface. Weekly self-reports were
deemed sufﬁciently frequent to allow early signs to be meaningfully de-
tected but not so frequent as to overburden participants, since beta-test
participants considered weekly app use acceptable but would not have
wanted it to be more frequent (Eisner et al., 2019).2.4. Procedure
2.4.1. Baseline assessments
An overview of all baseline and follow-up assessments is provided in
Fig. 1. At baseline, the Schizophrenia Proneness InstrumentAdult Version
interview (SPI-A) (Schultze-Lutter et al., 2007a) identiﬁed whether par-
ticipants had experienced basic symptoms beginning or increasing prior
to their most recent psychotic episode. Early signs (ESS) (Birchwood
et al., 1989) were assessed for the same period.
Psychotic symptoms and mood symptoms during the previous week
were assessed using the PANSS (Kay et al., 1987), PSYRATS (Psychotic
Symptom Rating Scales) (Haddock et al., 1999) and Hospital Anxiety
and Depression Scale (Zigmond and Snaith, 1983). Substance use was
assessed using a 4-point scale (Tarrier et al., 2006), medication adher-
ence using a 7-point scale (Kemp et al., 1996) and cognitions related to
imminent psychosis relapse using the Fear of Recurrence Scale (FoRSE)
(Gumley et al., 2015). Demographic information was gathered using a
standard questionnaire. Assessors were trained and supervised by senior
colleagues. Mean intra-class correlations (ICC) compared to gold stan-
dard PANSS ratings were excellent (positive = 0.92; negative = 0.83;
general = 0.89; total = 0.92).f using a smartphone app to assess early signs, basic symptoms and
/j.schres.2019.04.003
Fig. 1. Overview of assessments.
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Using SPI-A and ESS assessments, the researcher and participant de-
ﬁned a ‘relapse signature’ combining early signs and basic symptoms.
Items from the participant's relapse signaturewere entered into the Ex-
PRESS app so that individuals could monitor a personalized set of early
signs. Participants were trained on ExPRESS and asked to use it weekly
for 6 months or until relapse, whichever was sooner. Those owning an
android smartphone used their own phones and the remaining partici-
pants used a study phone. The latter received weekly text messages to
their own phone reminding them to use ExPRESS.
Participants were telephoned by the researcher (weekly for four
weeks; monthly thereafter) to encourage participation and trouble-
shoot any difﬁculties with app use. During the 3-month telephone call,
the researcher assessed the PSYRATS, ﬁve PANSS positive items (delu-
sions, hallucinations, suspiciousness, grandiosity, conceptual disorgani-
zation), and a subset of SPI-A items (Cognitive Disturbances (COGDIS)
and Cognitive-Perceptive (COPER)) (Schultze-Lutter et al., 2007a).
This was to screen for additional delusions or overlooked relapses and
to check app item validity.
The primary relapse deﬁnition (Wunderink et al., 2007) (Supple-
mentary Fig. 2) required a symptom increase for ≥1 week resulting in
a management change (casenote-reported medication change or in-
creased observation by the clinical team, including admission). Symp-
tom increase criteria, assessed via PANSS telephone interview (ﬁve
items: delusions, hallucinations, suspiciousness, grandiosity, conceptual
disorganization), were: for remitted individuals, an increase to ≥4 or an
increase of ≥2 points (whichever was higher) on any item; for non-
remitted individuals with all baseline PANSS positive items b5, at least
one item ≥5; for non-remitted individuals with ≥1 baseline item ≥5, an
increase to ≥4 or an increase of ≥1 point (whichever was higher) on
any item. Individuals' remission status was initially determined from
baseline PANSS using standard remission severity criteria (AndreasenPlease cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
psychotic symptoms o..., Schizophrenia Research, https://doi.org/10.1016/et al., 2005). To identify participants remitting during the app-use
phase, we modiﬁed these criteria to accommodate app content: partici-
pants scoring ≤3 for two consecutiveweeks on all app-assessed psychotic
symptom items (delusions, hallucinations, grandiosity, suspiciousness;
scaled the same as corresponding PANSS items) were classiﬁed as
remitted.
PANSS telephone interviews were triggered when app-reported
psychotic symptoms exceeded a pre-speciﬁed threshold (initially
equivalent to the symptom increase criteria). If symptom increase
criteria were met, the telephone assessment was repeated one week
later to check duration. If app-reported symptoms exceeded the thresh-
old two consecutive weeks without any increase in symptoms detected
during the resultant telephone call, the threshold for receiving a call was
recalibrated (for each app-assessed symptom, the new threshold was
one point above the average of the previous four app responses).
Two aspects of the above relapse assessment procedure were added
seven months into the study. Firstly, the original deﬁnition did not ac-
count for remission status, with identical symptom increase criteria ap-
plied to non-remitted and remitted individuals. Secondly, the telephone
call threshold recalibration was formerly absent, so participants with
high residual symptoms were telephoned every week. Following
these changes, four were deemed remitted at baseline, three as remit-
ted during the app-use phase, four had their telephone call threshold
recalibrated and ﬁve were unaffected.
The secondary relapse deﬁnition, assessed using casenotes alone, re-
quired a symptom increase for ≥1 week resulting in a management
change. For each participant, the relapse start date was recorded, with
verbatim extracts from casenotes describing changes in symptoms
and management. The researcher conducting casenote screening was
trained to protocol (Barrowclough et al., 2010); ratings on reliability
cases showed perfect correspondence with gold standard assessors (re-
lapse presence/absence kappa = 1.00; relapse start date ICC = 1.00).f using a smartphone app to assess early signs, basic symptoms and
j.schres.2019.04.003
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On longitudinal phase completion or dropout, face-to-face assess-
ments (SPI-A; PANSS positive items) and qualitative interviews were
conducted. The brief (average 6 min), audio-recorded qualitative inter-
view topic guide included: reasons for participation; researcher sup-
port; telephone call acceptability and ﬁnancial reimbursement; study
highlights and lowlights. PANSS positive items were assessed via tele-
phone within three days prior to face-to-face assessment for validity
checks.
2.4.4. Participant payment
Participants received: £10 per completed study phase; £10 monthly
to cover phone credit (longitudinal participants); £5 per telephone in-
terview (last 6 months of the study only; to test whether engagement
increased).
2.5. Study outcomes and analysis
2.5.1. Statistical analysis
Analyses were conducted in Stata (StataCorp, 2015), with
bootstrapping where appropriate, and considered statistically signiﬁcant
at p b 0.05. App-assessed items scored on a 4-point scale were linearly
transformed to a 7-point scale to aid comparison with other measures.
2.5.2. ExPRESS weekly monitoring: feasibility
Feasibilitywas assessed using descriptive statistics summarizing: re-
cruitment to baseline assessments, recruitment to longitudinal phase
(proportion of baseline participants eligible and consenting), app en-
gagement (percentage of assessments completed), timing of app re-
sponses across the 24-hour response window, proportion of standard
study telephone calls and telephone call PANSS assessments completed,
and proportion of study phones returned. The 6-month relapse ratewas
noted, to inform future power calculations. The pattern of app comple-
tion during the app-use phase was examined in a mixed-effects model
with a random effect of participant and a ﬁxed-effect of time. Effects
of baseline variables on percentage app completion were examined
using Spearman's correlation (continuous variables), Mann-Whitney
or Kruskal-Wallis test (categorical variables).
2.5.3. Relapse signatures (basic symptoms and early signs): validity
To measure concurrent validity, the number of app-reported basic
symptoms during the ﬁrst three and full six months of app use were
compared to retrospective telephone (3 months) and face-to-face
(6 months) researcher-rated SPI-A assessments using ICCs (two way
mixed, absolute agreement, single measures). Preliminary predictive
validity was assessed in two ways. Firstly, mixed-effects models were
estimated, with app-assessed psychotic symptoms as the dependent
variable, a ﬁxed-effect of early signs and/or basic symptoms and a ran-
dom effect of participant. Likelihood ratio tests explored whether
addingbasic symptoms to early signs improvedmodelﬁt. Secondly, pat-
terns of basic symptoms and early signs were examined graphically in
the participants meeting full or partial relapse deﬁnitions.
2.5.4. Relapse deﬁnition: validity
Validity was examined by comparing: 6-month relapse rates using
primary and secondary relapse deﬁnitions (kappa); telephone inter-
views of PANSS items and the same items assessed face-to-face (two
way mixed, absolute agreement, single measures ICC); researcher-
rated symptoms and app-reported symptoms. For the latter comparison,
the researcher-rated symptom variables came from a face-to-face inter-
view, where available, or telephone interview. Spearman's correlation
was calculated to aid comparison with previous studies (Palmier-Claus
et al., 2012) but this does not account for the nested data structure.
Therefore, mixed-effects models were constructed, with app-reported
symptoms as the dependent variable, a ﬁxed-effect of researcher-rated
symptoms and a randomeffect of participant. The ﬁxed-effect coefﬁcientPlease cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
psychotic symptoms o..., Schizophrenia Research, https://doi.org/10.1016can be interpreted as the average change in app-reported symptoms for
a 1-point change in researcher-rated symptoms.
2.5.5. Study procedures: acceptability
We used the framework method (Gale et al., 2013) to analyze verba-
tim transcriptions of qualitative interviews. The research teamdeveloped
the initial analytical framework using the topic guide and independently
coded two of the ﬁrst three transcripts each, updating the framework as
necessary. The ﬁrst author systematically coded the remaining tran-
scripts and charted the data into a framework matrix to aid discussion
and interpretation by the whole team.
3. Results
3.1. Sample characteristics
Demographic and clinical characteristics of longitudinal participants
are shown in Table 1.
3.2. ExPRESS weekly monitoring: feasibility
Fig. 2 shows recruitment and retention. Only 11% (22/193) of indi-
viduals that clinical staff considered potentially suitable participated in
baseline interviews. The main reasons for exclusion were that individ-
uals were ineligible, declined to participate, or were not given study in-
formation by staff. Most baseline participants (18/22) were eligible for
and consented to the longitudinal phase and engagement was high,
with 78% completing ≥33% app assessments and 72% completing ≥50%
app assessments. Most longitudinal participants (89%) completed a
qualitative interview. Thirteen participants used ExPRESS on a study
phone; all returned the phone in good condition except one who
returned it to a clinician, who lost it.
Participants completed 65% app assessments and 65% supportive
telephone calls. App-reported symptoms increased above the telephone
interview threshold 31 times, of which 18 (58%) resulted in completed
PANSS positive telephone interviews; participants were unavailable for
the remaining 13 telephone interviews. The distribution of app comple-
tion across the sample is shown in Fig. 3. Three clusters are apparent:
half the sample completed ≥90% of app assessments, four completed
60–70% and four completed b13% of assessments. The exception was
unexpectedly abroad for several months, precluding app completion;
while in the UK, their app completion was 60%.
Supplementary Fig. 3 shows app response timing across the 24-hour
responsewindow;most responses occurred in theﬁrst 12 h,with a sub-
stantial peak immediately after the initial alert (1.30 pm). Participants
responded to fewer prompts as the study progressed (OR = 0.89 per
week follow-up; p b 0.001; Supplementary Fig. 4). Percentage app com-
pletion was signiﬁcantly and inversely correlated with baseline depres-
sion and fear of relapse, with baseline anxiety approaching signiﬁcance
and all other baseline variables non-signiﬁcant (Table 1).
3.3. Relapse signatures (basic symptoms and early signs): validity
3.3.1. Descriptive statistics
Themean number of basic symptoms reported at baseline as having
begun or increased prior to a recent psychotic episode was 6.4 (sd =
4.3, range = 1–17); mean ESS score for this period was 84.4 (sd =
20.6, range = 41–121).
3.3.2. Concurrent validity
ICCs comparing the number of app-reported and researcher-rated
basic symptoms suggested poor agreement at 3 months (ICC = 0.37,
p = 0.307, n = 8; telephone call COPER/COGDIS items) but excellent
agreement at 6 months (ICC = 0.76, p b 0.001, n = 12; face-to-face
full SPI-A).f using a smartphone app to assess early signs, basic symptoms and
/j.schres.2019.04.003
Table 1
Clinical and demographic characteristics of longitudinal phase sample (n = 18).
Baseline variable Association between
baseline variable and
percentage app use
Frequency (percentage)
unless otherwise stated
Test
statistic
type
Test
statistic
value
P
value
Diagnosis
Schizophrenia 14 (77.8) U 23.00 0.622
Schizoaffective 4 (22.2)
PANSS subscales (mean, sd)
Positive 15.4 (5.4) ρ −0.22 0.380
Negative 15.1 (4.7) ρ −0.09 0.725
General 31.0 (8.8) ρ −0.37 0.128
Total 61.8 (16.8) ρ −0.26 0.308
PSYRATS subscales (mean, sd)
Delusions 6.6 (6.3) ρ −0.36 0.148
Hallucinations 17.4 (12.9) ρ −0.23 0.368
HADS subscales (mean, sd)
Anxiety 8.9 (6.1) ρ −0.48 0.052
Depression 7.6 (6.3) ρ −0.56 0.015
FoRSE subscales (mean, sd)
Fear of Relapse 14.5 (5.8) ρ −0.58 0.014
Intrusions 13.8 (5.6) ρ −0.21 0.419
Awareness 18.1 (6.1) ρ −0.34 0.163
Total 45.9 (14.7) ρ −0.40 0.128
Medication adherence
(median, range)
6 (3, 7) Χ2 4.57 0.188
Gender, n male 12 (66.7) U 20.00 0.141
Age (mean, sd) 37.9 (9.9) ρ −0.14 0.570
Education
Secondary 10 (55.6) Χ2 0.20 0.914
Further 5 (27.8)
Higher 3 (16.7)
Employment
Employed 2 (11.1) Χ2 4.38 0.195
Voluntary work 1 (5.6)
Retired 1 (5.6)
Unemployed 14 (77.8)
Ethnicity
Asian or Asian British 1 (5.6) Χ2 0.63 0.792
Black or Black British 2 (11.1)
White British 15 (83.3)
Marital status
Single 14 (77.8) Χ2 1.53 0.516
Married 2 (11.1)
Separated 2 (11.1)
Living arrangement
Alone 12 (66.7) Χ2 3.53 0.558
With family 4 (22.2)
Supported accommodation 2 (11.1)
Owns a smartphone 15 (83.3) U 15.50 0.520
Used a study phone 13 (72.2) U 26.50 0.580
Consent to give app data to
clinician
15 (83.3) U 13.00 0.278
Abbreviations: PANSS = Positive and Negative Syndrome Scale; PSYRATS = Psychotic
Symptom Rating Scales; HADS = Hospital Anxiety and Depression Scale; FoRSE = Fear
of Recurrence Scale;
Test statistics: U=Mann-WhitneyU test statistic; ρ=Spearman's correlation coefﬁcient;
Χ2 = Kruskall Wallis test statistic.
5E. Eisner et al. / Schizophrenia Research xxx (xxxx) xxxIn mixed-effects models (Table 3) both early signs and basic symp-
tomswere signiﬁcantly associatedwith all psychotic symptommeasures,
except grandiosity, at the same time point. Adding basic symptoms to
early signs improved model ﬁt in three cases.3.3.3. Prediction of psychotic symptoms (Table 3)
One week later: early signs signiﬁcantly predicted suspiciousness;
neither early signs nor basic symptoms predicted any other psychotic
symptom variables.
Two weeks later: basic symptoms approached signiﬁcance in
predicting suspiciousness; no other predictions two weeks later were
signiﬁcant.Please cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
psychotic symptoms o..., Schizophrenia Research, https://doi.org/10.1016/Three weeks later: early signs signiﬁcantly predicted psychotic
symptoms and hallucinations; basic symptoms signiﬁcantly predicted
psychotic symptoms and delusions, with hallucinations and suspicious-
ness approaching signiﬁcance; adding basic symptoms to early signs
improved model ﬁt for psychotic symptoms and delusions, with suspi-
ciousness approaching signiﬁcance.
3.3.4. Prediction of relapse
Graphs of app-assessed items for participants meeting full or partial
relapse deﬁnitions (Supplementary Fig. 5) indicate greater variability
over time in severity of app-assessed early signs and basic symptoms
than app- or researcher-assessed psychotic symptoms. Since they re-
spondmore than psychotic symptoms to relapse triggers and treatment,
this probably signiﬁes greater sensitivity to underlying changes rather
than more random noise.
3.4. Relapse deﬁnition: validity
Two participantsmet both primary and secondary relapse deﬁnitions,
and one met the secondary deﬁnition alone, a substantial agreement
(kappa = 0.76, p = 0.003). The relapse which met the secondary but
not primary deﬁnition appeared to be a false positive (see Supplementary
Textbox 1). Agreement between ﬁve PANSS positive items assessed dur-
ing a telephone call and the same items assessed face-to-face was ex-
tremely high (Table 2), with ICCs ranging from 0.94 to 0.96 (p b 0.001).
High agreement was also demonstrated for PSYRATS delusions (ICC =
0.97, p b 0.001) and hallucinations (ICC = 0.89, p b 0.001) subscales.
The correlation between researcher-rated symptoms and app-reported
symptoms was high, with Spearman's rho ranging from 0.80 to 0.87 (p
b 0.001; Table 2). Fixed-effects coefﬁcients from mixed-effects models
ranged from 0.66 to 1.08 (p b 0.05), with all conﬁdence intervals crossing
1.00.
3.5. Study procedures: acceptability
We report the acceptability of study participation (Supplementary
Table 1). A detailed analysis of ExPRESS's acceptability is reported else-
where (Eisner et al., 2019). Participants gave various reasons for taking
part, including altruism, wanting to increase knowledge about psycho-
sis, curiosity about the research, feeling it might help them personally
and previous positive research experiences. One individual, initially
attracted by the ﬁnancial reimbursement, became genuinely interested
in the study. Several participants reported liking answering the ques-
tions, enjoying their novelty and ﬁnding them easy to answer even dur-
ing difﬁcult weeks. Others enjoyed the normalizing effect of ExPRESS,
satisfaction of helping with research and increased understanding of
their illness.
All participants found study telephone interviews acceptable and
felt they received enough researcher support, with several mentioning
that the reminder texts were helpful. Participants commented that the
telephone calls were not intrusive and their frequencywas appropriate;
some found them encouraging and reassuring. Views about whether ﬁ-
nancial reimbursement for telephone interviews was needed were
mixed. Although not speciﬁcally asked about the baseline interview,
two participants mentioned ﬁnding it long and a little stressful initially;
another commented that he found it acceptable.
4. Discussion
This study demonstrates the feasibility and acceptability of using an
app for weekly monitoring of early signs, basic symptoms, psychotic
symptoms and relapse over a six-month period, alongside telephone
calls from a researcher. We show preliminary evidence of concurrent
and predictive validity: early signs and basic symptomswere separately
associated with most app-assessed psychotic symptom variables the
same week and with a number of psychotic symptoms variables threef using a smartphone app to assess early signs, basic symptoms and
j.schres.2019.04.003
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6 E. Eisner et al. / Schizophrenia Research xxx (xxxx) xxxweeks later, and adding basic symptoms to early signs improved model
ﬁt in most of these cases. App items showed high concurrent validity
with researcher-rated psychotic symptoms and basic symptoms over
six months. There was also excellent agreement between telephone
call and face-to-face assessed psychotic symptoms. The primary deﬁni-
tion of relapse, based on telephone interviews and casenotes, compared
well with a casenote-only deﬁnition but had better speciﬁcity.
Since this study has the longest app-use phase of any to date
reporting a symptommonitoring app in a sample with established psy-
chosis, participants' app engagement is of key interest. ParticipantsFig. 3. Distribution of app completion during the 6 mo
Please cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
psychotic symptoms o..., Schizophrenia Research, https://doi.org/10.1016completed 65% app assessments, with 78% completing ≥33% assess-
ments. Although lower than studies with a follow-up ≤2 months
(Ainsworth et al., 2013; Ben-Zeev et al., 2014; Meyer et al., 2018;
Palmier-Claus et al., 2012), this compares favorably to those with 3-
month (Bucci et al., 2018) or 5-month (Kumar et al., 2018) follow-up
periods. Unlike previous studies (Ainsworth et al., 2013; Ben-Zeev
et al., 2014; Bucci et al., 2018; Kumar et al., 2018; Palmier-Claus et al.,
2012), we used weekly (rather than daily) app assessments which ap-
pear to be better tolerated over longer follow-up periods. However,
the only study with a longer follow-up (14 months) (Niendam et al.,nth app-use period across the sample (n= 18).
f using a smartphone app to assess early signs, basic symptoms and
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Table 2
Comparison of three modes of assessing psychotic symptoms: face-to-face interview, telephone interview, self-report using app items.
Face-to-face vs. phone calla Researcher-ratedb vs. app-reported
ICC Spearman's rho Mixed effects modelc
Coefﬁcient 95% CI Coefﬁcient 95% CI Coefﬁcient 95% CI
Delusions 0.96⁎⁎ 0.92, 1.01 0.80⁎⁎ 0.66, 0.95 0.66⁎ 0.14, 1.18
Conceptual disorganization 0.96⁎⁎ 0.87, 1.05 – – – –
Hallucinations 0.94⁎⁎ 0.86, 1.03 0.87⁎⁎ 0.77, 0.97 1.08⁎⁎ 0.90, 1.26
Grandiosity 0.96⁎⁎ 0.77, 1.16 0.84⁎⁎ 0.69, 1.00 1.02⁎⁎ 0.85, 1.19
Suspiciousness 0.96⁎⁎ 0.91, 1.01 0.85⁎⁎ 0.73, 0.97 0.94⁎ 0.18, 1.68
PSYRATSd delusions 0.97⁎⁎ 0.91, 1.02 – – – –
PSYRATSd hallucinations 0.89⁎⁎ 0.70, 1.09 – – – –
⁎⁎ p b 0.001.
⁎ p b 0.05.
a Based on 14 or 15 cases depending on item.
b Face-to-face interview, where available, or telephone interview when no face-to-face interview available; based on 27–37 observations from 14 to 15 cases, depending on item.
c Mixed effects model with bootstrapping with app-reported symptoms as the dependent variable, a ﬁxed effect of researcher-rated symptoms and a random effect of participant.
d Psychotic Symptom Rating Scales.
7E. Eisner et al. / Schizophrenia Research xxx (xxxx) xxx2018) included daily app assessments and averaged 69% app comple-
tion in a clinical high risk and recent onset psychosis sample. Partici-
pants were paid per completed assessment which likely increased
engagement. Their young age may also have engendered higher app
completion since they are likely to be more familiar with smartphone
apps than our older sample with established psychosis (Bonet et al.,
2018). Although neither we, nor others (Meyer et al., 2018; Palmier-
Claus et al., 2012), found an effect of age on app completion, our sample
was possibly too small or had an insufﬁcient age range to detect this.
Other predictors of app engagement have been examined but a con-
sistent picture is yet to emerge (Killikelly et al., 2017). Studies have re-
ported that higher positive (Meyer et al., 2018; Palmier-Claus et al.,
2012), negative (Kumar et al., 2018; Meyer et al., 2018) or agitation/
mania symptoms (Kumar et al., 2018) predicted lower app engagement,
whereas the current study found a signiﬁcant effect of depression and
fear of relapse. Arguably, those who are more fearful of relapse and
more depressed are at greater risk of relapse (Conley, 2009; Gumley
et al., 2015), more likely to avoid help seeking (Gumley and Park, 2010)
and thus more difﬁcult for services to engage in treatment. If symptomTable 3
Mixed effects models examining whether app-assessed conventional early signs and basic sy
symptoms to conventional early signs improves model ﬁt (likelihood-ratio test).
Early signs
Prediction of: Coefﬁcient SE P value Observations
Simultaneous psychosis
Psychotic symptoms 0.435 0.059 b0.001 275
Hallucinations 0.556 0.076 b0.001 275
Delusions 0.347 0.076 b0.001 275
Suspiciousness 0.311 0.073 b0.001 274
Grandiosity 0.071 0.083 0.391 275
Psychosis 1 week later
Psychotic symptoms 0.104 0.075 0.169 223
Hallucinations 0.122 0.091 0.180 223
Delusions 0.117 0.089 0.190 223
Suspiciousness 0.194 0.080 0.016 222
Grandiosity −0.090 0.080 0.262 223
Psychosis 2 weeks later
Psychotic symptoms 0.028 0.086 0.744 209
Hallucinations 0.127 0.120 0.293 209
Delusions −0.027 0.097 0.778 209
Suspiciousness −0.023 0.084 0.789 208
Grandiosity 0.007 0.089 0.941 209
Psychosis 3 weeks later
Psychotic symptoms 0.192 0.076 0.011 206
Hallucinations 0.283 0.094 0.003 206
Delusions 0.138 0.096 0.152 206
Suspiciousness 0.056 0.078 0.472 205
Grandiosity 0.071 0.093 0.444 206
Bold values statistically signiﬁcance at p b 0.05.
Please cite this article as: E. Eisner, S. Bucci, N. Berry, et al., Feasibility o
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thesemay not suit everyone and take additional steps to engage these in-
dividuals. Interestingly, neitherwe, nor others (Kumar et al., 2018), found
that using a study phone signiﬁcantly reduced app engagement, despite
qualitative feedback suggesting that participants prefer their own phones
(Ainsworth et al., 2013; Eisner et al., 2019; Palmier-Claus et al., 2012). Re-
turn rate of study phones in the current study was excellent (92%), and
comparable to previous studies (Biagianti et al., 2017; Granholm et al.,
2012), contrasting with clinicians' fears that patients might lose/sell
study phones (Berry et al., 2017).
This study provides a novel approach to operationally deﬁning re-
lapse by using a combination of telephone interviews and casenotes.
While numerous relapse deﬁnitions exist, these rely on face-to-face as-
sessments or solely on casenotes (Eisner et al., 2013; Falloon et al., 1983;
Gleeson et al., 2010; Olivares et al., 2013). We suggest that remote re-
lapse assessment is more easily integrated into participants' lives, de-
creasing both participant and researcher burden; this is likely to
increase engagement and allow more frequent, long-term monitoring.
Our operational relapse deﬁnition compared well with a casenote-mptoms separately predict app-assessed psychotic symptoms and whether adding basic
Basic symptoms Likelihood-ratio test
Coefﬁcient SE P value Observations LR Chi2 P value
0.314 0.051 b0.001 275 12.20 b0.001
0.442 0.064 b0.001 275 17.49 b0.001
0.214 0.067 0.002 275 2.24 0.134
0.288 0.075 b0.001 274 11.23 b0.001
0.014 0.051 0.788 275 0.11 0.742
0.081 0.068 0.232 222 0.69 0.407
0.116 0.088 0.189 222 1.14 0.286
0.078 0.088 0.387 222 0.29 0.591
0.060 0.077 0.435 221 0.19 0.667
−0.107 0.071 0.131 222 1.26 0.263
0.084 0.067 0.211 208 2.39 0.122
0.132 0.103 0.202 208 1.85 0.174
0.067 0.078 0.388 208 1.96 0.162
0.121 0.068 0.075 207 6.47 0.011
0.044 0.080 0.577 208 0.45 0.501
0.174 0.067 0.009 205 6.25 0.012
0.162 0.091 0.075 205 1.63 0.201
0.216 0.090 0.017 205 11.02 b0.001
0.110 0.058 0.056 204 3.55 0.060
0.083 0.078 0.293 205 0.89 0.345
f using a smartphone app to assess early signs, basic symptoms and
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8 E. Eisner et al. / Schizophrenia Research xxx (xxxx) xxxonly deﬁnition but had better speciﬁcity, since the latter generated a
false positive. However, conversely, our operational deﬁnition may
have generated false negatives; since the proportion of unanswered
telephone calls was high (42%), some symptom increases may have
been missed. As the ﬁrst study comparing telephone and face-to-face
interview PANSS items, our ﬁnding of extremely high agreement be-
tween these is encouraging but needs replicating in a larger sample.
Nevertheless, this ﬁnding suggests that our deﬁnition may be compara-
ble to other relapse deﬁnitions that use PANSS positive items.
We found a strong association between app-reported and researcher-
rated psychotic symptoms, replicating previous ﬁndings (Niendam et al.,
2018; Palmier-Claus et al., 2012) and suggesting that symptommonitor-
ing apps are a valid means of assessing symptom course. Agreement be-
tween app- and researcher-assessed basic symptoms was also excellent
over 6 months, improving upon previous self-report measures of basic
symptoms which show poor concurrent validity (Mass et al., 1997;
Michel et al., 2016). Although we found low agreement at 3-month as-
sessment, keydifferences between the 3- and6-month SPI-A assessments
may explain this disparity: the 3-month researcher-rated assessmentwas
conducted via telephone rather than face-to-face, with a smaller sample
and only included a sub-set of SPI-A items.
There are a number of important limitations. Firstly, the sample was
small, precluding a deﬁnitive examination of predictive validity: sensitiv-
ity and speciﬁcity could not be calculated, making it difﬁcult to compare
with other early signs studies. Nonetheless, mixed-effects models (using
changes in psychotic symptoms as a proxy for relapse) and graphs of re-
lapsers provided sufﬁcient evidence of predictive validity to warrant fur-
ther investigation. Secondly, the sample is unlikely to be representative,
as the decline rate was high (42%), albeit comparable with other symp-
tom monitoring app studies (Ainsworth et al., 2013: ~30% decline; Bucci
et al., 2018: 30%; Ben-Zeev et al., 2014: 39%; Kumar et al., 2018: 44%;
Niendam et al., 2018: 47%; Palmier-Claus et al., 2012: ~50%). Thirdly, re-
searchers were not formally blind to participants' early signs or basic
symptoms prior to conducting PANSS telephone interviews; in practice
neither early signs nor basic symptoms were known but future studies
should use an independent, formally blinded assessor. Fourthly, regarding
the mixed-effects models, the dependent variable (psychotic symptoms)
and predictors (early signs and basic symptoms) are related experiences
which were self-reported by participants using the same method (an
app), increasing the risk of spurious correlations arising from common
method variance and expectancy effects. Fifthly, while baseline assess-
ments were conducted by a single assessor, a second assessor carried
out half the 6-month SPI-A assessments but inter-rater reliability was
not evaluated. Finally, since this was a feasibility study, protocol changes
weremade during data collection. However, these changes reﬁned the re-
lapse deﬁnition and reduced the number of telephone interviews.
In conclusion,we found that weekly app-based assessment of symp-
tomswas feasible, acceptable and valid over a sixmonth period, offering
support for a large-scale study using this methodology. More generally,
these ﬁndings provide further evidence that symptommonitoring tech-
nology could be a valuable addition to routinemental health service de-
livery, since they closely correspond to researcher-rated assessments
and are well-tolerated over an extended period of time.Conﬂict of interest
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